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Mechanisms to guard genomic integrity are critical to ensuring
the welfare and survival of an organism. Disruptions of genomic
integrity can result in aneuploidy, a large-scale genomic imbalance
caused by either extra or missing whole chromosomes (chromo-
somal aneuploidy) or chromosome segments (segmental aneuploi-
dy). A change in dosage of a single gene may not compromise the
well-being of an organism, but the combined altered dosage of
many genes due to aneuploidy disturbs the overall balance of gene
expression networks, resulting in decreased fitness and mortality
[1,2]. Chromosomal aneuploidy is a common cause of birth
defects—Down syndrome is caused by an extra copy of
Chromosome 21, and Turner syndrome by a single copy of the
X chromosome in females. Furthermore, methods that detect
segmental aneuploidy have uncovered small deletions or duplica-
tions of the genome in association with many disorders, such as
mental retardation. Chromosomal and segmental aneuploidies are
also frequent in cancer cells in which changes in copy number
paradoxically increase cell fitness but are unfavorable to survival of
the organism. A fundamental issue in biology and medicine is to
understand the effects of aneuploidy on gene expression and the
mechanisms that alleviate aneuploidy-induced imbalance of the
genome.
Chromosomal aneuploidy is caused by non-disjunction of
chromosomes in meiosis or mitosis, while segmental aneuploidy
involves breakage and ligation of DNA. In contrast, the sex
chromosomes provide an example of a naturally occurring
‘‘aneuploidy’’ caused by the evolution of a specific set of
chromosomes for sex determination that often differ in their copy
number between males and females. For example, in mammals
and in flies, females have two X chromosomes and males have one
X chromosome and a Y chromosome, resulting in X monosomy in
males. How does a cell or an organism respond to such different
types of aneuploidy, abnormal or natural? It turns out that the
overall expression level of a given gene is not necessarily in direct
relation to the copy number. Unique strategies have evolved to
deal with abnormal gene dosage to alleviate the effects of
aneuploidy by dampening changes in expression levels. What’s
more, the X chromosome has evolved sophisticated mechanisms
to achieve complete dosage compensation, not surprisingly, since
the copy number difference between males and females has been
evolving for a long time.
Gene Expression Responses to Altered Dosage in
Aneuploidy
There are two main outcomes from altered gene dosage in
aneuploidy in terms of transcript levels—either levels directly
correlate with gene dosage (primary dosage effect) or they are
unchanged/partially changed with gene dosage (complete or
partial dosage compensation) [3]. In the first scenario, a reduction
of the normal gene dosage in a wild-type (WT) diploid cell from a
symbolic dose value of 2 to a value of 1 after a chromosomal loss
or deletion would produce half as many gene products, while an
increase in gene dosage from 2 to 3, due to a chromosomal gain or
duplication, would produce 1.5-fold more products (Figure 1). In
the second scenario, the amount of products from altered gene
dosage would either equal or nearly equal that in WT cells, due to
complete or partial compensation (Figure 1).
Gene expression analyses of aneuploid cells or tissues in human,
mouse, fly, yeast, and plant provide examples of both primary
dosage effects and dosage compensation. Hence, changes in
expression levels due to chromosomal aneuploidy do not affect all
genes in the same manner. For example, in Down syndrome, 29%
of transcripts from human Chromosome 21 are overexpressed
(22% in proportion to gene dosage and 7% with higher
expression), while the rest of genes are either partially compen-
sated (56%) or highly variable among individuals (15%) [4].
Interestingly, dosage-sensitive genes, such as genes encoding
transcription factors or ribosomal proteins, are more likely to be
compensated to avoid harmful network imbalances [1,5]. This
basal dynamic dosage compensation could be due to buffering,
feedback regulation, or both, depending on the gene and the
organism [4,6–9]. Buffering, a passive process of absorption of
gene dose perturbations, is due to inherent non-linear properties of
the transcription system. In contrast, feedback regulation is an
active mechanism that detects abnormal transcript abundance and
adjusts transcription levels.
Sex Chromosome-Specific Dosage Compensation
Sex chromosome-specific dosage compensation evolved in
response to the dose imbalance between autosomes and sex
chromosomes in the heterogametic sex due to the different
number of sex chromosomes between the sexes—for example, a
single X chromosome and a gene-poor Y chromosome in males
and two X chromosomes in females. Compensatory mechanisms
that restore balance both between the sex chromosomes and
autosomes and between the sexes vary among species [10,11]. In
Drosophila melanogaster (fruit fly), expression from the single X
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such upregulation occurs in females. X upregulation also occurs in
Caenorhabditis elegans (round worm) and in mammals but in both
sexes [6,12]. Silencing of one X chromosome in mammalian
females and partial repression of both X chromosomes in C. elegans
hermaphrodites have been adapted to avoid too high an
expression level of X-linked genes in the homogametic sex. A
unified theme in these diverse mechanisms of sex chromosome
dosage compensation is coordinated upregulation of most X-
linked genes approximately two-fold to balance their expression
with that of autosomal genes present in two copies. This process
utilizes both genetic and epigenetic mechanisms to increase
expression of an X-linked gene once it has lost its Y-linked
partner during evolution.
While the mechanisms of X upregulation in mammals and
worms are not clear, Drosophila X upregulation is mediated by the
male-specific lethal (MSL) complex [10,13]. The MSL complex
binds hundreds of sites along the male X chromosome and
modifies its chromatin structure by MOF (males absent on the
first)–mediated acetylation of histone H4 at lysine 16. Other
histone modifications and chromatin-associated proteins, includ-
ing both activating and silencing factors, are also involved in the
two-fold upregulation of the Drosophila male X chromosome [14].
How these modifications coordinately work to fine-tune a doubling
of gene expression is still not well understood. Moreover, the basal
dynamic dosage compensation response observed in studies of
autosomal aneuploidy could also play a role in Drosophila X
upregulation [3]. An important question is how much this basal
response to the onset of aneuploidy contributes to sex chromo-
some–specific dosage compensation.
Fine-Tuning of the Drosophila X Chromosome
Adds a Special Layer of Regulation above a
Genome-Wide Response to Aneuploidy
In this issue of PLoS Biology, Zhang et al. [15] report that the
exquisitely precise X chromosome upregulation in Drosophila
utilizes both a basal response to aneuploidy and an X
chromosome–specific mechanism. The beauty of their experimen-
tal system, the S2 cell line derived from a male fly, is that it has a
defined genome with numerous segmental aneuploid regions, both
autosomal and X-linked. Thus, genomic responses to aneuploidy
could be queried both on autosomes and on the X chromosome,
the latter being associated to the MSL complex. Using second-
generation DNA- and RNA-sequencing, the authors carefully
examined the relationship between gene copy number and gene
expression in S2 cells before and after induced depletion of the
MSL complex. By this approach the effects of the MSL complex
on the genome have effectively been separated from those
triggered by a basal response to aneuploidy.
What Zhang et al. have found is that partial dosage
compensation of both autosomal and X-linked regions occurs even
in the absence of the MSL complex. This provides strong evidence
that basal dosage compensation mediated by buffering and
feedback pathways allows dosage compensation across the whole
genome. In the presence of the MSL complex, X-linked genes, but
not autosomal genes, become subject to an additional level of
regulation, which increases expression independent of gene copy or
expression levels. This feed-forward regulation of the X chromo-
some by the MSL complex ensures a highly stable doubling of
expression specific to this chromosome. Note that this feed-forward
regulation results in precise dosage compensation only when X dose
is half of the autosome dose, while insufficient or excessive X-linked
gene expression occurs at lower or higher X dose. Excessive X
expression has also been reported when ectopic expression of
MSL2 is induced in Drosophila females, which leads to binding of the
MSL complex to both X chromosomes and lethality [16].
The new findings by Zhang et al. implicate two levels of
regulation of the X chromosome: one basal mechanism that can
regulate both the X and the autosomes in the event of aneuploidy;
and a second feed-forward mechanism specific to the X and
regulated by the MSL complex to ensure doubling of X-linked
gene expression (Figure 2). The new study proposes that the basal
compensation mechanism provides a 1.5-fold increase in gene
expression and the feed-forward mechanism, another 1.35-fold,
resulting in a precise two-fold increase in expression of X-linked
genes. The specificity of the MSL-mediated mechanism to double
X-linked gene expression is ensured by the existence of DNA
sequence motifs specifically enriched on the X chromosome to
recruit the MSL complex only to this chromosome [14].
Autosomal aneuploidy would only trigger a response of the basal
dosage compensation pathway, which would result in a 1.5-fold
increase in expression of genes located within a monosomic
segment (Figure 2). It should be noted that since gene expression
levels were measured relative to whole genome expression (due to
normalization) a fold change in expression of genes in an
aneuploid segment could also be interpreted as a fold change in
expression of the rest of the genome.
How did such a precise mechanism evolve to ensure
appropriate expression of sex-linked genes? The feed-forward
process mediated by the MSL complex is a highly stable
epigenetic modification selected and maintained during the
evolution of heteromorphic sex chromosomes (Figure 2). Hetero-
morphic sex chromosomes have arisen from an ancestral pair of
autosomes, following inhibition of recombination between the
proto-Y chromosome that carries the male determinant and its
counterpart, the proto-X chromosome [13]. Gradual loss of Y-
linked genes due to lack of recombination could have happened
gene-by-gene or on a chromosomal segment-by-segment basis.
The human Y chromosome apparently evolved by a series of
large inversions leading to a rapid loss of large chromosomal
segments [17]. If the lost Y segments contained dosage sensitive
Figure 1. Expression levels change in response to altered gene
dose in aneuploidy. The transcript output from a given pair of
chromosomes in normal WT diploid cells is set as a value of 2. In case of
aneuploidy (monosomy or trisomy), the amount of transcript would be
strictly correlated with gene dose in the absence of a dosage
compensation mechanism (No DC). In the presence of partial DC, the
expression level per copy would be partially increased in monosomy or
partially decreased in trisomy, relative to the diploid level. In the
presence of complete DC, expression levels would be adjusted so that
the amount of transcripts is the same in monosomic or trisomic cells
compared to diploid cells.
doi:10.1371/journal.pbio.1000318.g001
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compensation response as observed in autosomal aneuploidy
(Figure 2). However, this type of dosage compensation is dynamic
and incomplete, as it is probably mediated by buffering or
feedback mechanisms. An organism might tolerate partial
imbalances as long as those were small, but extensive gene loss
from the Y chromosome would eventually have caused a
deleterious collective imbalance for multiple X-linked genes. A
progressive increase in the size of aneuploid X regions could have
reached a threshold of unsustainable stress on the basal dosage
compensation process. To relieve this stress and survive X
aneuploidy, specific mechanisms of dosage compensations
targeted to the X chromosome would be desirable. Such
mechanisms probably derived by recruiting pre-existing regula-
tory complexes, for example in the making of the MSL complex
in Drosophila. Indeed, one of the components of this complex is
MOF, a histone acetyltransferase also involved in autosomal gene
regulation [10,13]. Homologues of Drosophila MSL proteins also
exist in other organisms where they are involved in gene
regulation and DNA replication and repair but do not appear
to associate with the X chromosome, suggesting that the
components of X chromosome–specific complexes may differ
between organisms [18].
In conclusion, two mechanisms apparently collaborate to
achieve the approximate two-fold upregulation of the Drosophila
X chromosome: a dynamic basal dosage compensation mecha-
nism probably mediated by buffering and feedback processes; and
a feed-forward, sex chromosome–specific regulation chiefly
mediated by the MSL complex. In mammals, upregulation of
the X chromosome may also result from a combination of more
than one mechanism, some applicable to aneuploidy that may
arise anywhere in the genome and others that evolved to control
the X chromosome. High X-linked gene expression in mammalian
cells with two active X chromosomes—undifferentiated female
embryonic stem (ES) cells [19] and human triploid cells [20]—
suggests that X upregulation does not default in these cells. Thus,
in mammals, X upregulation may also be mediated by a highly
stable feed-forward mechanism that acts on top of a basal
aneuploidy response. In contrast, the sex chromosomes of birds
and silkworms, ZZ in males and ZW in females, seem to lack a
precise dosage compensation mechanism of the Z chromosome,
possibly due to the absence of a feed-forward process [21,22]. The
Figure 2. Evolutionary model of sex chromosome dosage compensation compared to the basal compensation response of an
autosome after a deletion. After the proto-Y chromosome evolved a gene with a male-determining function (green bar), it became subject to
gradual gene loss on a gene-by-gene or segment-by-segment basis due to lack of recombination between the proto-sex chromosomes. If the lost
region on the proto-Y chromosome contained dosage sensitive genes such as those that encode transcriptional factors (yellow bars), this would have
triggered a basal dosage compensation response (yellow faucet) on the proto-X chromosome and led to a partial (1.5-fold) increase of expression
(small arrows). The same basal dosage compensation process would also modify a deleted region on an autosome (A) in an abnormal cell. Dosage-
insensitive genes (black bars) may escape this process. When broader regions were lost on the proto-Y chromosome, the collective imbalance effects
of multiple aneuploid genes would have become highly deleterious and the increased load of aneuploidy could have stressed the basal mechanism
of dosage compensation. Survival was achieved by recruiting regulatory complexes such as the MSL complex (red faucet) to aneuploid X segments
(red regions), to further increase gene expression (big arrows) and rescue the X monosomy. This feed-forward sex chromosome–specific regulation
would provide 1.35-fold increase in expression, which together with the basal dosage compensation (1.5-fold increase) would achieve the
approximate two-fold upregulation of most genes on the present day X chromosome. In contrast, large-scale deleterious autosomal aneuploidy
would be lost due to lack of a specific sex-driven compensatory mechanism.
doi:10.1371/journal.pbio.1000318.g002
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regulatory genes, or else selection for sexual traits may have
favored the retention of gene expression imbalances between
males and females. Male and female mammals display significant
expression differences of a subset of genes that escape X
inactivation and thus have higher expression in females [23].
Whether such genes play a role in female-specific functions is
unknown. Future work to uncover the actual molecular mecha-
nisms underlying the basal and feed-forward regulatory pathways
should help to fully understand the role of these processes in
different organisms, both in response to the acute onset of
aneuploidy and in evolution of sex-specific traits. Loss or
dysregulation of dosage compensation mechanisms could be
important in birth defects and in diseases, such as cancer, where
aneuploidy is common; exploring approaches to enhance dosage
compensation may be useful to relieve aneuploidy-related diseases.
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